RxDoctor Payments Data

Alexander Tschantz

Family · Huntington, WVNPI 1245827054

Payments from drug & device makers

$1,879in general payments, 2019–2025

Across 51 payments — averaging $36.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$760
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$212
  • Cvrx, Inc.$202
  • Impulse Dynamics (USA) Inc.$173
  • Kestra Medical Technology Services, Inc.$158
  • Bayer$125
  • plus $249 from 6 others

What the payments were for

  • Food & beverage$1,879100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,879 in reported general payments places this provider in the 75th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$32,848
Medicare patients
223
Services billed
425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan288$407,917
FarxigaDapagliflozin Propanediol226$278,656
CamzyosMavacamten25$207,887
JardianceEmpagliflozin153$194,527
EliquisApixaban178$193,995
XareltoRivaroxaban12$18,920
Repatha SyringeEvolocumab20$18,888
Sildenafil Citrate13$6,657
Metoprolol Succinate366$4,806
Spironolactone447$3,110
Bumetanide74$3,019
Eplerenone19$2,207
Midodrine Hcl13$2,001
Ranolazine ErRanolazine32$1,965
Atorvastatin Calcium149$1,241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$53$407,917288 claims
AstraZenecaFarxiga$760$278,656226 claims
E.r. Squibb & Sons, L.L.C.Camzyos$15$207,88725 claims
Boehringer IngelheimJardiance$14$194,527153 claims
PfizerEliquis$20$193,995178 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,507 family providers in West Virginia.

Other family in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →